Novartis's antipsychotic Fanapt launched in the US - update
This article was originally published in Scrip
Executive Summary
Novartis has launched its twice-daily oral atypical antipsychotic Fanapt (iloperidone) in the US for the acute treatment of schizophrenia in adults.